-- Preclinical Study Presented at 2013 Annual Meeting of the American Association for Cancer Research (AACR) -- -- Study on Mechanism of Cancer Metastasis also ReportedA-- WASHINGTON, April 8, 2013 (GLOBE NEWSWIRE) --AImmunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company mainly dedicated to the development of monoclonal antibody-based products for the targeted therapy of cancer, autoimmune and other serious conditions, today announced the development of a fresh class of antibody-cytokine conjugates using the Company's patented DOCK-AND-LOCKa (DNLa) system technology. Potent anti-tumor activity was demonstrated by these DNLa complexes in preclinical studies. The Organization has previously reported the growth of antibody-directed interferon-alpha 2b (IFN alpha 2b) processes. (To learn more, please reference the Company's press release at www.immunomedics.com/pdfs/news/2009/PR04222009A.pdf). Veltuzumab-IFN alpha 2b may be the most sophisticated product from this band of IFN alpha-based DNLa processes, and is currently being developed for improved therapy of B-cell malignancies, partly supported by way of a grant from the Small Company Innovation Research method of the National Cancer Institute totaling $2.8 million. While working equally to IFN-alpha in eliciting anti-viral, anti-tumor, and immune-modulating activities, IFN-lambda will be considered as a potential alternative to present IFN-alpha therapeutic sessions because of its more restricted cellular targets. Antibody-targeted IFN- lambda may further improve its potency, safety and pharmacokinetics. In the present research, 3 DNLTM processes of IFN- lambda, specified (E1 )- lambda 1, (15 )- lambda 1, and (C2 )- lambda 1, were produced by site-specifically conjugating IFN- lambda 1 to 3 of the Company's exclusive humanized antibodies, hRS7 (anti-TROP-2), hMN-15 (anti-CEACAM6), and hL243 (anti-HLA-DR), respectively. These antibody-cytokine conjugates were assessed in human malignant cell lines of cervix, colon, esophagus, lung, liver, and skin. Targeting of the antibody-cytokine conjugates to antigen-expressing cells significantly increased the total amount of IFN- lambda 1 localized at the cell surface. Because of this, (E1 )- lambda 1 inhibited the in vitro expansion of the cervical, lung and esophageal cancer cell lines at less than 1 picomolar (pm) focus, which was 1,000-fold livlier than industrial IFN- lambda 1. Likewise, the anti-proliferation action of (15 )- lambda 1 was enhanced ~100-fold in esophageal and cervical cancer cells, however not in CEACAM6-negative lung cancer cells. Further exploration is warranted by "these promising results, attributable to increased localization and stronger binding to antibody-targeted cells, as possible cancer therapeutics," said Cynthia L. Sullivan, President and Chief Executive Officer. Cancers are generally believed to be based on single cells that are genetically mutated, resulting in lots of divisions resulting in an growing tumefaction that eventually spreads to remote and regional organs. Cancer deaths usually are as a result of this metastasis affecting the new organs invaded. The initiating cells in many cases are known as cancer stem cells. How these become heterogeneous populations of cancer cells within the original tumor and even in the metastases may be the subject of intense new study, which has also centered on the tumor's microenvironment and how cancer cells interact with their nearby supportive cells. In a different poster presentation at the exact same AACR Annual Meeting, the Organization reported that genes of human cancer jump into surrounding normal cells by fusion of both cells. This study was done in cooperation with experts from the Garden State Cancer Center, Center for Molecular Medicine and Immunology in Morris Plains, NJ, and the Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, NIH, in Bethesda, MD. This team of boffins discovered an exchange of individual genes to standard hamster cells when cells from areas involved by Hodgkin's lymphoma from two people were implanted to mice. In all, 7 of 24 human genes analyzed were contained in the malignant tumors developing in the hamsters for extended periods of 5 to 6 years, with evidence of metastasis in the hamsters within 21 days of the original grafting of the human tumors. By means of delicate DNA coloring of the tumefaction cells, the researchers demonstrated that human and hamster DNA were within single cancer cells, addressing fused cells of both species. "These findings may explain how cancers create and change as time passes, spreading by metastasis to other organs by overcoming defense to the cancer cells and might lead to healing strategies," mentioned the lead investigator, Dr. David M. Goldenberg, Chief Medical Officer and Chief Medical Officer of Immunomedics, and President of the Middle for Molecular Medicine and Immunology. About Immunomedics Immunomedics is a New Jersey-based biopharmaceutical business mostly centered on the development of monoclonal antibody-based services and products for the targeted therapy of cancer, autoimmune and other significant diseases.AWe have developed numerous higher level proprietary technologies that permit us to create humanized antibodies that can be used either alone in unlabeled or "naked" form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or contaminants, in each case to create very targeted agents.AUsing these technologies, we've constructed a pipe of therapeutic solution candidates that utilize a few different systems of action.AWe also have a big part control in IBC Pharmaceuticals, Inc., which will be creating a story DOCK-AND-LOCKa (DNLa) method with us for building fusion proteins and multifunctional antibodies, and a new method of providing imaging and therapeutic agents precisely to disease, especially different solid cancers (colorectal, lung, pancreas, etc.), by proprietary, antibody-based, pretargeting techniques. We believe that our account of intellectual property, including roughly 220 productive patents in the United States and more than 400 international patents, shields our solution prospects and systems. For extra information on us, please visit our website at http://www.immunomedics.com/ blocked::http://www.immunomedics.com/">www.immunomedics.com. The data on our internet site doesn't, nevertheless, form part of this news release. That discharge, in addition to historical data, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing agreements (including the timing and amount of conditional payments), forecasts of future operating results, likely partnerships, and capital raising activities, involve significant risks and uncertainties and precise results could differ materially from those stated or implied herein. Facets that might cause such differences include, but are not confined to, risks associated with any cash payment that the Company might obtain in connection with a sublicense involving a third party and UCB, which can be not within the Company's get a grip on, new product development (including clinical trials consequence and regulatory requirements/actions), our dependence on our certification associates for the further development of epratuzumab and veltuzumab for non-cancer signs, competitive risks to advertised products and availability of necessary capital and other sources of funds on appropriate terms, if, as well as the risks discussed in the Company's filings with the Securities and Exchange Commission.AThe Company is not under any obligation, and the Company specifically disclaims any obligation, to update or modify any forward-looking statements, whether consequently of new data, future events or otherwise. Connected Articles
No comments:
Post a Comment